Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Research: RG3039 drug can extend survival, improve function in spinal muscular atrophy mouse models

In a new publication that appears in Human Molecular Genetics, the laboratory of Christine DiDonato, PhD reports on their pharmacological characterization of the drug RG3039, demonstrating that it can extend survival and improve function in two spinal muscular atrophy (SMA) mouse models.

5 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

New avatar system could provide quick and effective therapy for schizophrenia

An avatar system that enables people with schizophrenia to control the voice of their hallucinations is being developed by researchers at UCL with support from the Wellcome Trust.

31 May 2013

Queen's University Belfast scientists awarded research grants to tackle tropical diseases

Queen's University Belfast has been announced as a Grand Challenges Explorations winner, an initiative founded by the Bill & Melinda Gates Foundation. Scientists at the University's Institute for Global Food Security have been awarded grants to pursue two Innovative global health and development research projects aimed at tackling tropical diseases.

31 May 2013

Research discovery may lead to development of new therapies for neurological disorders

For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

29 May 2013

FAPESP funds $680 million to support 17 RIDCs

The Brazilian funding agency for scientific and technological research S-o Paulo Research Foundation, FAPESP, based in the state of S-o Paulo, announced an investment estimated in US$ 680 million to support 17 Research, Innovation and Dissemination Centers for a period of up to eleven years, subject to continuation reviews on years 2, 4 and 7.

22 May 2013

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.

17 May 2013

Research findings may pave way to new treatment for Alzheimer's disease in humans

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment.

14 May 2013

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

9 May 2013

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC).

7 May 2013

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL) today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

7 May 2013

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Researchers explore biological processes of stem cell division

The human body contains trillions of cells, all derived from a single cell, or zygote, made by the fusion of an egg and a sperm. That single cell contains all the genetic information needed to develop into a human, and passes identical copies of that information to each new cell as it divides into the many diverse types of cells that make up a complex organism like a human being.

6 May 2013

Pharmapendium adds new module to benefit researchers and toxicologists

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium, the leading source of preclinical, clinical and post-market data, has added a new module to its content base, the Metabolizing Enzymes and Transporters Module.

6 May 2013

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

One of the biggest challenges with Alzheimer's disease (AD) is that by the time physicians can detect behavioral changes, the disease has already begun its irreversibly destructive course.

26 Apr 2013

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

Thermo Fisher Scientific Inc., the world leader in serving science, today debuted several innovations in bioprocessing technologies and systems that address the evolving requirements of drug discovery and production for global biopharmaceutical and pharmaceutical manufacturers.

From Thermo Fisher Scientific Inc. 26 Apr 2013

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Case Western Reserve's Technology Transfer Office has granted an exclusive license of a novel Alzheimer's Disease (AD) treatment strategy to spinoff company ReXceptor Inc., which plans to initiate early-stage human clinical trials of the medication within the next few months.

26 Apr 2013

Drug Discovery News and Research

Further Reading

PRISM Pharma announces closing of $15 million Series C financing

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Research: RG3039 drug can extend survival, improve function in spinal muscular atrophy mouse models

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

New avatar system could provide quick and effective therapy for schizophrenia

Queen's University Belfast scientists awarded research grants to tackle tropical diseases

Research discovery may lead to development of new therapies for neurological disorders

FAPESP funds $680 million to support 17 RIDCs

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Research findings may pave way to new treatment for Alzheimer's disease in humans

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Isis begins clinical study of ISIS-STAT3 in patients with metastatic liver cancer

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Researchers explore biological processes of stem cell division

Pharmapendium adds new module to benefit researchers and toxicologists

Researchers create "designer" tracer for earlier diagnosis and better treatments of Alzheimer's

Thermo Fisher Scientific brings several innovations in bioprocessing technologies and systems

Rexceptor receives exclusive license for novel treatment of Alzheimer's disease

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News